University of Leicester
Browse
943648.pdf (1.4 MB)

Targeting BCL2-Proteins for the Treatment of Solid Tumours

Download (1.4 MB)
journal contribution
posted on 2015-12-23, 10:16 authored by Meike Vogler
Due to their central role in the regulation of apoptosis, the antiapoptotic BCL2-proteins are highly promising targets for the development of novel anticancer treatments. To this end, several strategies have been developed to inhibit BCL2, BCL-XL, BCL-w, and MCL1. While early clinical trials in haematological malignancies demonstrated exciting single-agent activity of BCL2-inhibitors, the response in solid tumours was limited, indicating that, in solid tumours, different strategies have to be developed in order to successfully treat patients with BCL2-inhibitors. In this review, the function of the different antiapoptotic BCL2-proteins and their role in solid tumours will be discussed. In addition, a comprehensive analysis of current small molecules targeting these antiapoptotic BCL2-proteins (e.g., ABT-737, ABT-263, ABT-199, TW-37, sabutoclax, obatoclax, and MIM1) will be provided including a discussion of the results of any clinical trials. This analysis will summarise the potential of BCL2-inhibitors for the treatment of solid tumours and will unravel novel approaches to utilise these inhibitors in clinical applications.

History

Citation

Advances in Medicine Volume 2014 (2014), Article ID 943648, 14 pages

Version

  • VoR (Version of Record)

Published in

Advances in Medicine Volume 2014 (2014)

Publisher

Hindawi Publishing Corporation

issn

2356-6752

eissn

2314-758X

Acceptance date

2014-08-15

Copyright date

2014

Available date

2015-12-23

Publisher version

http://www.hindawi.com/journals/amed/2014/943648/

Language

en

Usage metrics

    University of Leicester Publications

    Categories

    Keywords

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC